Third, we conjugate drugs and PEG chains of various lengths to anti-HER2-scFv to generate small format FPDC targeting HER2-positive breast cancer cells, as a potentially promising strategy to achieve deep tumor penetration. Here, ERBB2 is linked to breast cancer.